Lunai Bioworks Inc.

    Lunai Bioworks Inc.

    NNASDAQ:RENB
    - -
    USD
    - -
    - -
    Lunai Bioworks Inc.
    NASDAQ:RENB
    (Nasdaq Stock Market)

    Recent

    price

    - -

    P/E

    ratio

    - -

    div

    yld

    - -

    ROIC.AI

    2011
    2011
    2012
    2013
    2014
    2016
    2017
    2018
    2019
    2020
    2021
    2022
    2023
    2024
    2025
    TTM
    USD
    - -
    - -
    - -
    - -
    - -
    0.04
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Revenue per Share
    - -
    -0.07
    -0.06
    -0.08
    -3.16
    -1.82
    -1.75
    -2.88
    -4.8
    -2.46
    -5.67
    -21.59
    -7.05
    -9.07
    -10.78
    -7.15
    Basic EPS, GAAP
    - -
    -0.04
    -0.05
    -0.06
    -2.71
    -1.54
    -0.96
    -1.99
    -2.46
    -2.3
    -4.38
    -3
    -2.1
    -1.13
    -0.48
    -0.39
    Free Cash Flow per Basic Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Dividend per Share
    - -
    - -
    -0.08
    -0.15
    -29.19
    -27.59
    -23.19
    -15.84
    -14.05
    -13.85
    -19.27
    -38.9
    -43.37
    -34.09
    -30.92
    -27.72
    Book Value per Share
    - -
    - -
    -0.03
    -0.1
    4.39
    -0.81
    1.15
    -3.57
    1.74
    -0.06
    1.72
    -0.12
    -1.38
    -2.81
    -1.66
    -1.05
    Tangible Book Value per Share
    - -
    1
    1
    1
    1
    1
    1
    2
    4
    5
    5
    5
    6
    10
    17
    18
    Basic Weighted Avg Shares
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Sales/Revenue/Turnover
    - -
    - -
    - -
    - -
    - -
    -4,959.04
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Operating Margin (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Depreciation Expense
    - -
    - -
    - -
    - -
    -2
    -2
    -2
    -6
    -18
    -11
    -27
    -113
    -40
    -88
    -178
    -131
    Net Income, GAAP
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    - -
    -4,057.24
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Profit Margin (%)
    - -
    - -
    - -
    - -
    3
    -1
    1
    15
    11
    8
    19
    3
    -8
    -28
    -28
    -19
    Working Capital
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    7
    7
    6
    1
    1
    - -
    - -
    LT Debt
    - -
    - -
    - -
    - -
    3
    -1
    2
    159
    173
    166
    175
    73
    47
    132
    -21
    -13
    Total Equity
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    -62.23
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)

    Capital Structure

    USD

    •

    in mil. unless spec.
    Mar'25
    Jun'25
    Sep'26
    ST Debt
    7
    10
    2
    LT Borrowings
    - -
    - -
    - -
    LT Finance Leases
    - -
    - -
    - -
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    16
    18
    23
    Market Capitalization
    9
    5
    26

    Working Capital

    USD

    •

    in mil. unless spec.
    Mar'25
    Jun'25
    Sep'26
    Total Current Assets
    4
    1
    1
    Cash, Cash Equivalents & STI
    2
    - -
    1
    Accounts Receivable, Net
    - -
    - -
    - -
    Inventories
    - -
    - -
    - -
    Total Current Liabilities
    29
    29
    20
    Payables & Accruals
    20
    18
    17
    ST Debt
    7
    10
    2
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    978.11%
    -4.34%
    -116.18%
    Free Cash Flow
    36.01%
    2.03%
    -28.68%
    Net Income, GAAP
    95.77%
    123.53%
    101.31%
    Sales/Revenue/Turnover
    - -
    - -
    - -
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -
    2026
    - -
    - -
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2024
    -1.42
    -0.69
    -5.4
    - -
    -9.07
    2025
    -2.76
    -0.45
    0.01
    - -
    -10.78
    2026
    0.13
    - -
    - -
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -
    2026
    - -
    - -
    - -
    - -
    - -
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • accessnewswire.com

      Lunai Bioworks Advances Biomarker Discovery Preclinical Program in Parkinson's Disease, Positioning for Strategic Pharma Partnerships

    • accessnewswire.com

      Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock Split

    • accessnewswire.com

      Lunai Bioworks subsidiary BioSymetrics and Brigham and Women's Hospital Awarded NIH STTR Grant to Develop AI-Powered Platform for Alcohol Use Disorder Therapeutics

    • benzinga.com

      Top 3 Health Care Stocks You'll Regret Missing In Q3

    • accessnewswire.com

      Lunai Bioworks Inc. Retains American Defense International

    • accessnewswire.com

      Renovaro Inc. (NASDAQ: RENB) Mentioned in RealClearDefense Article on AI and Biodefense Risks

    • accessnewswire.com

      Renovaro Secures Key AI Patents, Strengthening Market Position in $20B Biomedical AI Sector

    • accessnewswire.com

      Peer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor Efficacy

    • accessnewswire.com

      Renovaro Strengthens Balance Sheet Through Debt Conversion and Advances AI-Driven Initiatives

    • accessnewswire.com

      Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs

    • globenewswire.com

      Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform

    • globenewswire.com

      UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

    • globenewswire.com

      Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

    • globenewswire.com

      Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform

    • globenewswire.com

      Renovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA Diagnostics

    • globenewswire.com

      Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs

    • globenewswire.com

      Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine

    • globenewswire.com

      Renovaro Provides Update to Definitive Agreement with Predictive Oncology

    • globenewswire.com

      Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology

    • globenewswire.com

      Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine